The PMDA thereby clarifies its intention to promote global clinical trials in which Japan is involved.

Parallel distribution is defined as the distribution of a centrally authorised medicinal product from one Member State to another by a pharmaceutical company independent of the marketing authorisation holder.

This ATP brings changes to the labelling and classification of some existing harmonized substances and adds new harmonized substances in Part 3 of Annex VI.